Introduction: Although previous studies have investigated the impact of perirenal fat on chronic kidney disease (CKD), there are yet no systematic reviews and meta-analyses to investigate the association between perirenal fat and CKD. Methods: We searched six English electronic databases including PubMed, Scopus, Web of Science, Ovid, Embase, and the Cochrane Library to select clinical studies that reported the relationship between perirenal fat and CKD, and the search period ranged from the establishment of the database to September 10, 2024. Two researchers independently screened the studies and ultimately compared the literature. Stata (version 16 SE; College Station, TX, USA) software was used for statistical analysis. Results: A total of eight articles that included 2,576 patients were included in this meta-analysis. The results showed a significant association between perirenal fat and CKD (95% CI: 0.48–0.65, p = 0.00), and no heterogeneity was detected between these two groups (I2 = 31.06%, p = 0.18). Subgroup analysis revealed that whether it is diabetic nephropathy, nephropathy caused by abnormal cardiac function, or primary CKD, perirenal fat is closely related to them. Conclusion: The results of this systematic review and meta-analysis showed that perirenal fat thickness is closely related to CKD. Clinicians should pay attention to relevant indicators when diagnosing and treating patients with CKD.

With the economic and technological developments of society, the global prevalence of obesity has considerably increased and is continuing to rise. Traditionally, obesity has been classified by the degree of body mass index (BMI) elevation. However, the role of BMI in predicting obesity-related risk diseases is limited [1]. Extensive research has found that visceral adipose tissues are metabolically active and are the source of humoral and cellular inflammation in obese patients [2]. Obesity has a close link with many diseases such as atherosclerosis [3], esophageal adenocarcinoma [4], and diabetic nephropathy [5].

Kidney diseases are among the most common diseases in the world. It has been shown that the total number of patients with chronic kidney disease (CKD), acute kidney injury, and renal replacement therapy exceeds 850 million [6, 7]. Worldwide, 1.2 million people died from CKD in 2017, especially in Oceania, sub-Saharan Africa, and Latin America; the burden of CKD is much higher than expected for development levels [8]. Generally, glomerular filtration rate (GFR) and albuminuria are used to assess the severity of kidney diseases [9]. The perirenal fat tissue surrounding the kidneys was originally thought to provide only mechanical support to the kidneys. However, an increasing number of studies have shown that perirenal fat tissue is more closely associated with kidney disease than other visceral fat deposits [10]. Furthermore, current studies propose that perirenal fat may have a higher predictive value for CKD in type 2 diabetes mellitus [11‒13]. The interaction of adipose tissue with the kidney is critical for normal kidney function and the kidney’s response to injury [14], and it may be related to inflammatory cytokines [15] and cardiorenal dysfunction [16].

To our knowledge, there are no previous systematic reviews and meta-analyses examining the relationship between perirenal fat and CKD. Therefore, we conducted a comprehensive systematic review and meta-analysis to investigate the association between perirenal fat and prediction of CKD.

Search Strategy

The search period is from the establishment of the database to September 10, 2024. Six English electronic databases including PubMed, Scopus, Web of science, Ovid, Embase, and the Cochrane Library were searched for relevant publications on perirenal fat and CKD. The search strategies are as shown ((((((((((((((perirenal fat[Title/Abstract]) OR (perinephric fat[Title/Abstract])) OR (perirenal fat[Title/Abstract])) OR (perinephric adipose[Title/Abstract])) OR (perirenal fatty[Title/Abstract])) OR (perinephric fatty[Title/Abstract])) OR (perirenal fat Tissue[Title/Abstract])) OR (perinephric adipose tissues[Title/Abstract])) OR (perirenal fatty tissue[Title/Abstract])) OR (perinephric fatty tissue[Title/Abstract])) OR (perirenal fat tissue[Title/Abstract])) OR (perinephric fat tissue[Title/Abstract])) OR (perirenal fat thickness[Title/Abstract])) OR (perinephric fat thickness[Title/Abstract])) OR (perirenal fat pad[Title/Abstract]).

Inclusion and Exclusion Criteria

We set the following inclusion and exclusion criteria according to the PICO(S) (Participants, Intervention, Comparators, Outcomes [Study design]) model. The study protocol was previously registered at PROSPERO (CRD42024514011). Participants: patients with a diagnosis of CKD. Intervention: not applicable. Comparators: non-CKD patients. Outcomes: primary indicators of perirenal fat thickness.

Study Design: Retrospective Cohort Study

Studies were excluded for the following reasons: (1) full text could not be obtained; (2) case reports, letters, reviews, conference abstracts, animal experiments, and expert opinions; and (3) studies were not published in English.

Study Selection

The literature management software NoteExpress was used to filter and eliminate literature. First, two researchers (P.F.K. and B.J.S.) screened the titles to eliminate duplicates, reviews, and conference papers. Then, both researchers read the literature abstracts to further determine their inclusion or exclusion based on the association between perirenal fat and CKD. Finally, they read the full text of the selected articles to confirm their inclusion in the meta-analysis. During this process, both researchers conducted independent screenings and compared the remaining literature. Disagreements were resolved by consensus where possible and/or by a third reviewer when necessary. The flowchart of the study is shown as a PRISMA flowchart in Figure 1.

Fig. 1.

PRISMA flowchart of the literature search and selection procedure.

Fig. 1.

PRISMA flowchart of the literature search and selection procedure.

Close modal

Risk of Bias and Quality Assessment

The Newcastle-Ottawa Scale (NOS) is designed to assess the quality of these studies.

Data Extraction

A seven-item standardized and preselected data extraction form was used to record the data included in the study, with the following headings: (1) Author, (2) Year of publication, (3) Country, (4) Sample size, (5) Detection method, (6) Perirenal fat thickness, (7) Glomerular filtration rate.

Data Analysis

Stata (version 16 SE; College Station, TX, USA) software was used for statistical analysis of this meta-analysis. Measurement data are presented as mean ± standard deviation. The effective rate using relative risk and the 95% confidence interval (CI) are the effect indicators. Heterogeneity between groups was measured using I2, when I2 ≤ 50% and p ≥ 0.10, multiple similar studies can be considered to have low heterogeneity, when I2 > 50% or p < 0.10, multiple similar studies can be considered to have high heterogeneity. Different heterogeneity was matched to different effect models (low, fixed; high, random) [17]. Further analysis of differences was carried out, such as sensitivity analysis and subgroup analysis, to reduce within-group heterogeneity.

Study Selection Results

As shown in Figure 1, there were 9,719 articles matching our search strategy, and a total of 4,216 articles remained after removing duplicate articles. After reviewing the titles and abstracts, 4,183 irrelevant articles were further excluded. Finally, after reading the full texts, 8 articles were included in this meta-analysis.

Characteristics of the Included Studies

The total number of participants in our meta-analysis was 2,576 from eight studies. All included studies were retrospective cohorts [11, 18‒24]. Among these included studies, the most commonly used method to measure perirenal fat thickness was computed tomography (55.6%), while the remainder used ultrasound. Online supplementary Table S1 shows the characteristics of the studies included in the analysis (for all online suppl. material, see https://doi.org/10.1159/000543989).

Quality Assessment

Most of the included studies were of good quality and had an NOS score of >6 points. The minimum score for inclusion studies was 6 points. Online supplementary Table S2 describes the detailed quality assessment of these studies.

Perirenal Fat Thickness and CKD

We analyzed eight studies with 2,576 participants to assess the relationship between perirenal fat thickness and CKD. A combined analysis of these studies showed a significant association between perirenal fat thickness and CKD (95% CI: 0.48–0.65, p = 0.00), and no heterogeneity was detected between these two groups (I2 = 31.06%, p = 0.18) (Fig. 2).

Fig. 2.

Forest plot of perirenal fat thickness between CKD and no-CKD.

Fig. 2.

Forest plot of perirenal fat thickness between CKD and no-CKD.

Close modal

Subgroup Analyses

Two articles analyzed the relationship between perirenal fat and CKD secondary to cardiac dysfunction, these studies demonstrated that pericardial fat was significantly associated with CKD Secondary to Cardiac Dysfunction (95% CI: 0.49–0.92, p < 0.00001). Five studies examined the relationship between pericardial fat and diabetic nephropathy, and the pooled analysis of these articles demonstrated a significant association between pericardial fat and the presence of diabetic nephropathy (95% CI: 0.39–0.60, p < 0.00001) (Fig. 3).

Fig. 3.

Subgroup analyses of perirenal fat thickness between CKD and no-CKD.

Fig. 3.

Subgroup analyses of perirenal fat thickness between CKD and no-CKD.

Close modal

Publication Bias Assessment of Studies

The initial analysis of publication bias was conducted through visual inspection, which indicated a potential presence of bias due to observed asymmetry. Consequently, we performed the Egger test, revealing a one-tailed p value of 0.204 for the regression intercept, suggesting an absence of publication bias. Figure 4 illustrates funnel plots for both observational and estimated studies.

Fig. 4.

Analysis of publication bias by funnel plot.

Fig. 4.

Analysis of publication bias by funnel plot.

Close modal

Main Findings

In this systematic review and meta-analysis, we found that increased perirenal fat thickness is closely associated with the development of CKD, and the results of our subgroup analysis showed that regardless of whether CKD was caused by cardiac dysfunction, type 2 diabetes, or primary CKD, the perirenal fat thickness may significantly affect the progression of them.

Comparison with Existing Literature

Based on the above data, we performed a further review and analyzed why perirenal fat affects CKD.

Local Compression to the Kidneys by Perirenal Fat

The distance between the perirenal fat and kidneys is small enough for the two organs to interact. When perirenal fat increases, Gerota’s fascia can limit the expansion of adipose tissue, which may exert physical pressure on the renal vessels and renal parenchyma. Compression of the renal parenchyma may result in changes in the renal hemodynamics, including increased interstitial hydrostatic pressure and decreased renal blood flow and tubular flow velocity [25, 26]. Studies have found that with increasing perirenal fat volume, these surrounding adipose tissues can compress the renal vasculature, leading to pathological activation of the renin-angiotensin-aldosterone system (RAAS) and reduced renal perfusion, as well as venous compression and internal hemodynamic changes, which could lead to decreased kidney function [27‒29].

Lipid Metabolism Disorders Affect Kidney Function

Lipid metabolism-related factors (HDL, LDL, TG, TC) are significantly associated with the progression of CKD by affecting local lipid deposition around the kidney. Alla et al. [30] noted that TC, TG, and fatty acids contribute to the progression of CKD due to dysregulated in podocytes, endothelial cells, and tubular cells; moreover, kidney parenchymal TC accumulation also contributes to CKD progression. Lee et al. [31] pointed out that higher LDL-C levels are associated with an increased risk of adverse renal outcomes than lower LDL-C levels (70–99, 100–129, and ≥130 mg/dL vs. <70 mg/dL, respectively). Nam et al. [32] believed that both low and high serum HDL-C levels may be detrimental to patients with non-dialysis CKD. Li et al. [33] pointed out that the TC/HDL-C ratio had predictive value in the progression of CKD.

However, we found an interesting phenomenon wherein no association between BMI and the progression of CKD was noted, but WC significantly affects the progression of CKD. This is also similar to the findings of a prospective cohort study by Cejka et al. [34] who found that WC significantly affects the risk of death in patients with CKD, but BMI does not. A meta-analysis conducted by Betzler et al. [35] also showed that BMI was not significantly associated with CKD. In clinical research and practice, systemic adiposity is often assessed by BMI, while visceral fat is often more closely related to WC, and higher WC means increased visceral fat and cardio-metabolic risk [36]. From the above results, we can speculate that WC, rather than BMI, may be a higher reliable indicator of kidney function.

Blood Pressure Affects Kidney Function

The kidney plays a crucial role in regulating blood pressure, and renal disease can lead to elevated blood pressure, while hypertension may further exacerbate the progression of renal impairment. Moreover, it is posited that alterations in vascular structures, glomeruli, and tubular compartments induced by hypertension contribute to the development of CKD [37]. Li et al. [38] identified perinephric fat as a specific target for both the onset and progression of hypertension; notably, resection of this adipose tissue can result in systemic arterial system expansion. Conversely, several studies have also reported a positive correlation between perirenal fat thickness and diastolic blood pressure levels [39‒41]. Our findings may be influenced by the limited number of studies included.

Possible Mechanisms through Which Perirenal Fat Affects CKD

The mechanism through which increased perirenal fat elevates the risk of CKD remains unclear. Renal lipotoxicity is induced by multiple pathophysiological mechanisms, such as inflammation, oxidative stress generated by reactive oxygen species, insulin resistance, and the activation of the renin-angiotensin system [42, 43]. It is widely recognized that obesity is a chronic state of low-grade inflammation, the accumulation of triglycerides causes adipocyte hypertrophy, thereby leading to the secretion of free fatty acids, leptin, pro-inflammatory cytokines such as TNF-α, interleukin-1β, interleukin-6 [44], jointly promoting insulin resistance [45]. Reactive oxygen species play a vital role in the detrimental effects of renal adipose accumulation in obese patients. Lipid overload aggravates endoplasmic reticulum stress via oxidative pathways, forming a feedback loop that exacerbates renal injury [46]. Therefore, these studies have demonstrated that perirenal fat may intricately lead to the onset of CKD through mechanisms such as lipotoxicity, chronic inflammation, and oxidative stress.

Strengths and Limitations

This study initially demonstrated an association between perirenal fat and CKD, followed by a subgroup analysis. While it presents certain advantages over previous related studies, it also has notable limitations. First, unexplained heterogeneity exists due to the low methodological quality of the included studies, which precludes the attainment of high-strength evidence; thus, the evaluation results should be interpreted with caution in clinical practice. Second, the small sample size in each study affects the external validity of our findings. Third, although two reviewers conducted the entire review process independently, variations in defining perirenal fat may introduce selection bias. Finally, most data originate from Asia, resulting in a lack of representation from South America, Oceania, and Africa.

Our systematic review and meta-analysis showed that thickening of perirenal fat affects the progression of CKD. It is recommended that clinicians pay more attention to this indicator to evaluate the possibility of incorporating them into CKD scores.

Ethical approval and consent were not applicable because this study is based exclusively on published literature.

The authors declare that they have no competing interests.

This work was supported by the Project of the Department of Integrated Traditional Chinese and Western Medicine and Minority Medicine, National Administration of Traditional Chinese Medicine (No. 2023384).

P.K. and B.S. designed and conceptualized the research, wrote the manuscript, and contributed equally to this study and shared first authorship. J.H. and C.W. analyzed the data. X.C. revised it. All authors have read and agreed to the published version of the manuscript.

All data generated or analyzed during this study are included in this article and its online supplementary materials, and further inquiries can be directed to the corresponding author.

1.
Busebee
B
,
Ghusn
W
,
Cifuentes
L
,
Acosta
A
.
Obesity: a review of pathophysiology and classification
.
Mayo Clin Proc
.
2023
;
11
:
S0025
6196
.
2.
Alexopoulos
N
,
Katritsis
D
,
Raggi
P
.
Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis
.
Atherosclerosis
.
2014
;
233
(
1
):
104
12
.
3.
Rallidis
LS
,
Baroutsi
K
,
Zolindaki
M
,
Karagianni
M
,
Varounis
C
,
Dagres
N
, et al
.
Visceral adipose tissue is a better predictor of subclinical carotid atherosclerosis compared with waist circumference
.
Ultrasound Med Biol
.
2014
;
40
(
6
):
1083
8
.
4.
Massl
R
,
van Blankenstein
M
,
Jeurnink
S
,
Hermans
JJ
,
de Haan
MC
,
Stoker
J
, et al
.
Visceral adipose tissue: the link with esophageal adenocarcinoma
.
Scand J Gastroenterol
.
2014
;
49
(
4
):
449
57
.
5.
Akbas
EM
,
Demirtas
L
,
Ozcicek
A
,
Timuroglu
A
,
Bakirci
EM
,
Hamur
H
, et al
.
Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic nephropathy
.
Int J Clin Exp Med
.
2014
;
7
(
7
):
1794
801
.
6.
Jager
KJ
,
Kovesdy
C
,
Langham
R
,
Rosenberg
M
,
Jha
V
,
Zoccali
C
.
A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases
.
Kidney Int
.
2019
;
96
(
5
):
1048
50
.
7.
Zakrocka
I
,
Załuska
W
.
Kynurenine pathway in kidney diseases
.
Pharmacol Rep
.
2022
;
74
(
1
):
27
39
.
8.
GBD Chronic Kidney Disease Collaboration
.
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
.
Lancet
.
2020
;
395
(
10225
):
709
33
.
9.
Levey
AS
,
Coresh
J
.
Chronic kidney disease
.
Lancet
.
2012
;
379
(
9811
):
165
80
.
10.
Huang
N
,
Mao
EW
,
Hou
NN
,
Liu
YP
,
Han
F
,
Sun
XD
.
Novel insight into perirenal adipose tissue: a neglected adipose depot linking cardiovascular and chronic kidney disease
.
World J Diabetes
.
2020
;
11
(
4
):
115
25
.
11.
Chen
X
,
Mao
Y
,
Hu
J
,
Han
S
,
Gong
L
,
Luo
T
, et al
.
Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes
.
Diabetes
.
2021
;
70
(
10
):
2322
32
.
12.
Lamacchia
O
,
Nicastro
V
,
Camarchio
D
,
Valente
U
,
Grisorio
R
,
Gesualdo
L
, et al
.
Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients
.
Nephrol Dial Transpl
.
2011
;
26
(
3
):
892
8
.
13.
Roever
L
,
Tse
G
,
Biondi-Zoccai
G
.
Perirenal fat and chronic kidney disease in patients with diabetes
.
Diabetes
.
2021
;
70
(
10
):
2190
1
.
14.
Zhu
Q
,
Scherer
PE
.
Immunologic and endocrine functions of adipose tissue: implications for kidney disease
.
Nat Rev Nephrol
.
2018
;
14
(
2
):
105
20
.
15.
Maimaituxun
G
,
Fukuda
D
,
Izaki
H
,
Hirata
Y
,
Kanayama
HO
,
Masuzaki
H
, et al
.
Levels of adiponectin expression in peri-renal and subcutaneous adipose tissue and its determinants in human biopsied samples
.
Front Endocrinol
.
2019
;
10
:
897
.
16.
D’Marco
L
,
Puchades
MJ
,
Panizo
N
,
Romero-Parra
M
,
Gandía
L
,
Giménez-Civera
E
, et al
.
Cardiorenal fat: a cardiovascular risk factor with implications in chronic kidney disease
.
Front Med
.
2021
;
8
:
640814
.
17.
Harris
RJ
,
Deeks
JJ
,
Altman
DG
,
Bradburn
MJ
,
Harbord
RM
,
Sterne
JAC
.
Metan: fixed-and random-effects meta-analysis
.
Stata J
.
2008
;
8
(
1
):
3
28
.
18.
Cho
IJ
,
Lee
SE
,
Kim
DH
,
Pyun
WB
.
Clinical and imaging parameters associated with impaired kidney function in patients with acute decompensated heart failure with reduced ejection fraction
.
J Cardiovasc Imaging
.
2023
;
31
(
4
):
169
77
.
19.
Xu
S
,
Ma
J
,
Zheng
Y
,
Ren
R
,
Li
W
,
Zhao
W
, et al
.
Para-perirenal fat thickness is associated with reduced glomerular filtration rate regardless of other obesity-related indicators in patients with type 2 diabetes mellitus
.
PLoS One
.
2023
;
18
(
10
):
e0293464
.
20.
Cho
IJ
,
Wi
J
,
Lee
SE
,
Kim
DH
,
Pyun
WB
.
Perirenal fat and kidney function deterioration in patients with acute decompensated heart failure
.
Int J Heart Fail
.
2023
;
5
(
1
):
36
47
.
21.
Shen
FC
,
Cheng
BC
,
Chen
JF
.
Peri-renal fat thickness is positively associated with the urine albumin excretion rate in patients with type 2 diabetes
.
Obes Res Clin Pract
.
2020
;
14
(
4
):
345
9
.
22.
Li
Y
,
Liu
Y
,
Gao
L
,
Tian
C
.
Renal stiffness measured by shear wave elastography and its relationship with perirenal fat in patients with chronic kidney disease
.
J Clin Ultrasound
.
2024
;
52
(
1
):
3
12
.
23.
Yang
Y
,
Ma
Y
,
Cheng
Y
,
Xu
Y
,
Fang
Y
,
Ke
J
, et al
.
The perirenal fat thickness was independently associated with serum uric acid level in patients with type 2 diabetes mellitus
.
BMC Endocr Disord
.
2022
;
22
(
1
):
210
.
24.
Hu
H
,
Liang
W
,
Zhang
Z
,
Liu
Z
,
Chu
F
,
Bao
Y
, et al
.
The utility of perirenal fat in determining the risk of onset and progression of diabetic kidney disease
.
Int J Endocrinol
.
2022
;
2022
:
2550744
.
25.
Rea
DJ
,
Heimbach
JK
,
Grande
JP
,
Textor
SC
,
Taler
SJ
,
Prieto
M
, et al
.
Glomerular volume and renal histology in obese and non-obese living kidney donors
.
Kidney Int
.
2006
;
70
(
9
):
1636
41
.
26.
Hall
JE
,
Crook
ED
,
Jones
DW
,
Wofford
MR
,
Dubbert
PM
.
Mechanisms of obesity-associated cardiovascular and renal disease
.
Am J Med Sci
.
2002
;
324
(
3
):
127
37
.
27.
Hall
JE
,
do Carmo
JM
,
da Silva
AA
,
Wang
Z
,
Hall
ME
.
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms
.
Circ Res
.
2015
;
116
(
6
):
991
1006
.
28.
Naumnik
B
,
Myśliwiec
M
.
Renal consequences of obesity
.
Med Sci Monit
.
2010
;
16
(
8
):
RA163
70
.
29.
Boorsma
EM
,
Ter Maaten
JM
,
Voors
AA
,
van Veldhuisen
DJ
.
Renal compression in heart failure: the renal tamponade hypothesis
.
JACC Heart Fail
.
2022
;
10
(
3
):
175
83
.
30.
Mitrofanova
A
,
Merscher
S
,
Fornoni
A
.
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
.
Nat Rev Nephrol
.
2023
;
19
(
10
):
629
45
.
31.
Lee
C
,
Park
JT
,
Chang
TI
,
Kang
EW
,
Nam
KH
,
Joo
YS
, et al
.
Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: results from the KNOW-CKD
.
Nutr Metab Cardiovasc Dis
.
2022
;
32
(
2
):
410
9
.
32.
Nam
KH
,
Chang
TI
,
Joo
YS
,
Kim
J
,
Lee
S
,
Lee
C
, et al
.
Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD
.
J Am Heart Assoc
.
2019
;
8
(
6
):
e011162
.
33.
Li
W
,
Du
Z
,
Wei
H
,
Dong
J
.
Total cholesterol to high-density lipoprotein cholesterol ratio is independently associated with CKD progression
.
Int Urol Nephrol
.
2022
;
54
(
8
):
2057
63
.
34.
Cejka
V
,
Störk
S
,
Nadal
J
,
Schmid
M
,
Sommerer
C
,
Sitter
T
,
GCKD Study Investigators
, et al
.
Differential prognostic utility of adiposity measures in chronic kidney disease
.
J Ren Nutr
.
2023
;
33
(
4
):
546
54
.
35.
Betzler
BK
,
Sultana
R
,
Banu
R
,
Tham
YC
,
Lim
CC
,
Wang
YX
, et al
.
Association between body mass index and chronic kidney disease in asian populations: a participant-level meta-analysis
.
Maturitas
.
2021
;
154
:
46
54
.
36.
Sanches
FM
,
Avesani
CM
,
Kamimura
MA
,
Lemos
MM
,
Axelsson
J
,
Vasselai
P
, et al
.
Waist circumference and visceral fat in CKD: a cross-sectional study
.
Am J Kidney Dis
.
2008
;
52
(
1
):
66
73
.
37.
Wang
L
,
Wang
J
,
Zhang
Y
,
Zhang
H
.
Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023
.
Ren Fail
.
2024
;
46
(
1
):
2310122
.
38.
Li
P
,
Liu
B
,
Wu
X
,
Lu
Y
,
Qiu
M
,
Shen
Y
, et al
.
Perirenal adipose afferent nerves sustain pathological high blood pressure in rats
.
Nat Commun
.
2022
;
13
(
1
):
3130
.
39.
De Pergola
G
,
Campobasso
N
,
Nardecchia
A
,
Triggiani
V
,
Caccavo
D
,
Gesualdo
L
, et al
.
Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects
.
BMC Cardiovasc Disord
.
2015
;
15
:
108
.
40.
Manno
C
,
Campobasso
N
,
Nardecchia
A
,
Triggiani
V
,
Zupo
R
,
Gesualdo
L
, et al
.
Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects
.
Eat Weight Disord
.
2019
;
24
(
1
):
67
72
.
41.
Guo
XL
,
Tu
M
,
Chen
Y
,
Wang
W
.
Perirenal fat thickness: a surrogate marker for metabolic syndrome in Chinese newly diagnosed type 2 diabetes
.
Front Endocrinol
.
2022
;
13
:
850334
.
42.
Ali
MM
,
Parveen
S
,
Williams
V
,
Dons
R
,
Uwaifo
GI
.
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
.
J Clin Transl Endocrinol
.
2024
;
36
:
100341
.
43.
Castro
BBA
,
Foresto-Neto
O
,
Saraiva-Camara
NO
,
Sanders-Pinheiro
H
.
Renal lipotoxicity: insights from experimental models
.
Clin Exp Pharmacol Physiol
.
2021
;
48
(
12
):
1579
88
.
44.
Cypess
AM
.
Reassessing human adipose tissue
.
N Engl J Med
.
2022
;
386
(
8
):
768
79
.
45.
Nakashima
A
,
Kato
K
,
Ohkido
I
,
Yokoo
T
.
Role and treatment of insulin resistance in patients with chronic kidney disease: a review
.
Nutrients
.
2021
;
13
(
12
):
4349
.
46.
Kounatidis
D
,
Vallianou
NG
,
Stratigou
T
,
Voukali
M
,
Karampela
I
,
Dalamaga
M
.
The kidney in obesity: current evidence, perspectives and controversies
.
Curr Obes Rep
.
2024
;
13
(
4
):
680
702
.